It’s been about a week and a half since the last email.
No dramatic reason — just took a beat to reset and plan out what’s coming next.
But the timing actually works out, because something happened last week that’s worth talking about.
The FDA approved Foundayo (orforglipron) on April 1st.
It’s a once-daily GLP-1 pill made by Eli Lilly, and it’s different from oral Wegovy in one important way: no food or water restrictions.
You can take it any time of day, with a meal, without a meal — doesn’t matter.
Why that’s a bigger deal than it sounds:
Oral Wegovy (semaglutide) is a peptide.
It’s fragile in the gut, so you have to take it on an empty stomach with minimal water and then wait 30 minutes before eating or drinking.
A lot of people struggle with that. Compliance drops when the dosing protocol is inconvenient.
Foundayo isn’t a peptide at all — it’s a small molecule that activates the same GLP-1 receptor.
Because it’s not a peptide, it survives stomach acid without any special protection, which eliminates the timing restrictions.
The clinical numbers:
In the ATTAIN-1 trial with over 3,100 participants, people on the highest dose lost an average of 11.2% of their body weight over 72 weeks.
That’s roughly 27 pounds.
Oral Wegovy’s trials showed 16–17% loss on the highest dose.
So Wegovy’s pill produces more weight loss on paper, but Foundayo’s convenience factor could make it a better real-world option for people who won’t stick with the fasting requirements.
What this means for the biohacking world:
The GLP-1 space is moving fast.
We went from injectable-only to two oral options in less than four months.
For anyone running research protocols involving GLP-1 agonists — whether for body recomp, metabolic optimization, or appetite regulation — the landscape of available tools just expanded significantly.
It also raises an interesting question: if small molecules can now hit the same receptors as peptides, what does that mean for the future of peptide-based compounds?
That’s a longer conversation for another day.
This week I’m going to cover some compounds and topics we haven’t touched yet — starting tomorrow with a copper peptide that’s flying under the radar in the longevity space.
Good to be back.